GENE ONLINE|News &
Opinion
Blog

2022-06-08| M&A

EQT and Mubadala to Acquire Envirotainer in $3 Billion Deal

by Fujie Tham
Share To

Swedish EQT Private Equity and Abu Dhabi’s Mubadala Investment Company have agreed to make a majority investment in Envirotainer, the leading medical freight company specializing in cold containers for transporting temperature-sensitive pharmaceutical products.

The pair will be acquiring Envirotainer from Cinven and Novo Holdings, which purchased the business back in 2018 for about $1 billion. Envirotainer played a major role during the peak of the COVID-19 pandemic, the company’s containers had transported more than half (250 million doses) of global vaccines by air cargo as of early 2021.

Related article: RNA Therapeutics Beyond Vaccines

 

Envirotainer’s Mission-Critical Role in Healthcare Ecosystem

 

The Company developed and marketed the first shipping container with an active temperature control system in 1995, enabling it to meet the industry’s complex need for rapid and safe cold chain shipments of biopharmaceuticals at low and stable temperatures. Today, Envirotainer supports the transportation of approximately 2 million doses of medicines per day, ensuring medicines are safely delivered to destinations around the globe with its fleet of 6700 refrigerated containers.

“This long-term partnership will strengthen Envirotainer and help us deliver on our purpose of enabling access to life-saving pharmaceuticals. At the same time, this investment, from such esteemed investors, confirms the strength of Envirotainer’s business model and the company’s very exciting future,” Peter Gisel-Ekdahl, Envirotainer’s CEO said.

EQT and Mubadala will seek to support Envirotainer’s next phase of growth by accelerating expansion in the Asia Pacific region while leveraging EQT’s local-with-locals approach and Mubadala’s global network to do so. Both firms will help scale the newly launched CryoSure lineup and continue the successful roll-out of the third-generation Releye air cargo platform.

EQT manages assets of around €77 billion globally, and its focus ranges from real estate, technology, and healthcare. Recently, EQT has been restructuring its holdings in the healthcare and logistics sector. In 2021, EQT and Goldman Sachs acquired Parexel for $8.5 billion.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Ajinomoto to Acquire Forge Biologics for $620 Million to Boost Gene Therapy Capabilities
2023-11-14
M&A
Strides Pharma to Sell Manufacturing Facility in Cost Optimization Move
2023-10-31
M&A
Novo Nordisk Acquires Ocedurenone with $1.3B for Hypertension and Cardiovascular Disease
2023-10-18
LATEST
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top